This segment focuses on developing and commercializing therapies for immunological and inflammatory diseases. Key research and development activities include the development of GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease (IBD). The technology platform involves oral small molecule development and gut-targeting strategies. The therapeutic area covered is IBD, with the goal of improving patient outcomes by reducing inflammation in the gut. Market positioning involves developing a novel, gut-targeted therapy with potentially fewer systemic side effects compared to existing treatments. Future opportunities include expanding the IBD pipeline and exploring other immunological indications. Clinical trials and regulatory aspects are critical for advancing GB004 through the development process.

This segment is dedicated to the discovery and development of innovative cancer therapies. Research and development efforts are centered on GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of primary central nervous system lymphoma (PCNSL), and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. The segment leverages small molecule inhibitor technology to target key signaling pathways in cancer cells. The therapeutic area is PCNSL, with the aim of providing more effective and less toxic treatment options for patients. Market positioning involves developing targeted therapies with improved efficacy and safety profiles. Future opportunities include expanding the oncology pipeline and exploring other cancer indications. Clinical trials and regulatory approvals are essential for bringing these therapies to market.

This segment is focused on addressing the unmet medical needs of patients with pulmonary arterial hypertension (PAH). The primary focus is on GB002, an inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor. Research and development activities include clinical trials to evaluate the safety and efficacy of GB002 in PAH patients. The technology platform involves inhaled drug delivery and multi-kinase inhibition. The therapeutic area is PAH, with the goal of improving pulmonary hemodynamics and exercise capacity in patients. Market positioning involves developing a novel inhaled therapy with potentially improved efficacy and reduced systemic side effects. Future opportunities include expanding the PAH pipeline and exploring other pulmonary indications. The collaboration with Chiesi Group is a key partnership in this area.